Table 3.

Crude and adjusted Cox proportional hazards models using inverse probability treatment weighting by propensity score. Exposure time with concomitant (methotrexate, ciclosporin, fumaric acid esters, hydroxycarbamide) immunosuppressive medication use is adjusted for, with exposure time to two immunosuppressive therapies classed as concomitant in the nonbiologic cohort

	Infliximab (all lines; N = 422) against nonbiologic therapies (95% CI)	P‐values	Infliximab (first line; N = 105) against nonbiologic therapies (95% CI)	P‐values	Infliximab (all lines) against methotrexate (95% CI)	P‐values	Infliximab (first line) against methotrexate (95% CI)	P‐values
Crude hazard ratio (HR) overall time (95% confidence interval)	3·41 (2·38–4·90)	< 0·001	4·19 (2·42–7·26)	< 0·001	4·39 (2·85–6·75)	< 0·001	5·16 (2·82–9·46)	< 0·001
Adjusted HR Overall	1·95 (1·01–3·75)	0·046	1·37 (0·50–3·74)	0·541	2·96 (1·58–5·57)	0·001	1·97 (0·71–5·46)	0·193
HR for concomitant immunosuppressant therapy	1·34 (0·61–2·97)	0·464	3·06 (1·41–6·67)	0·005	1·24 (0·59–2·60)	0·577	2·45 (1·02–5·88)	0·045
Crude HR for time 0–6 months	4·73 (2·07–10·81)	< 0·001
Adjusted HR for time 0–6 months	3·49 (1·14–10·70)	0·029
Crude HR for time 6–12 months	6·99 (3·63–13·45)	< 0·001
Adjusted HR for time 6–12 months	2·99 (1·10–8·14)	0·032
Crude HR for time 1–2 years	2·27 (1·08–4·76)	0·030
Adjusted HR for time 1–2 years	2·03 (0·61–6·79)	0·249